V.D. MENDELEVICH

Kazan State Medical University

  Contact details:

Mendelevich V.D. – D. Sc. (medicine), Professor, Head of the Department of Medical and General Psychology

Address: 49 Butlerov St., Kazan, 420012, tel.: +7 (843) 238-60-74, e-mail: [email protected]

 The paper analyzes the problem of using ethical standards when prescribing psycho pharmacotherapy under the requirement of strictly following the principles of evidence-based medicine. It is stated that many psychiatrists are skeptical about evidence-based medicine, as it is oriented towards the clinical, not scientific, facts. The conclusion is made that full and comprehensive information about all the available proofs of the efficiency and safety of the prescribed drugs must be provided to the patient. It is claimed that in modern conditions the role of the patient’s therapeutic qualification increases.

Key words: biomedical ethics, psycho pharmacotherapy, evidence-based medicine.

REFERENCES

1. Zakon RF “O psikhiatricheskoy pomoshchi i garantiyakh prav grazhdan pri ee okazanii” ot 2.07.1992 no. 3185-1 [The Law of the Russian Federation “On Psychiatric Assistance and Guarantees of the Rights of Citizens When It Is Provided” dated 2.07.1992 No. 3185-1], available at: http://www.consultant.ru/document/cons_doc_LAW_4205/
2. Neznanov N.G., Martynikhin I.A., Mosolov S.N. Diagnosis and therapy of anxiety disorders in the Russian Federation: the results of a survey of psychiatrists. Sovremennaya terapiya psikhicheskikh rasstroystv, 2017, no. 2, pp. 2–13 (in Russ.).
3. Mendelevich V.D. Psychopathological doctrine in national narcology and the problem of evidence-based medicine. Obozrenie psikhiatrii i meditsinskoy psikhologii, 2013, no. 3, pp. 33–38 (in Russ.).
4. Mendelevich V. Bioethical differences between drug addiction treatment professionals inside and outside the Russian Federation. Harm reduction Journal, 2011, vol. 8, p. 15.
5. Krupitskiy E.M., Bortsov A.V. Printsipy dokazatel’noy meditsiny v addiktologii. Rukovodstvo po addiktologii [Principles of evidence-based medicine in addictology. Guidelines for addictology]. Saint Petersburg: “Rech’”, 2007. Pp. 140–150.
6. Federal’nye klinicheskie rekomendatsii. Rossiyskoe obshchestvo psikhiatrov [Federal clinical guidelines. Russian Society of Psychiatrists]. Moscow, 2013, available at: https://psychiatr.ru/download/1353?view=1&name=KlinRekomend_Organika_16dekabrya13.pdf
7. Ioannidis J.P. The Mass Production of Redundant, Misleading, and Conflicted Systematic Reviews and Meta-analyses. Milbank Q, 2016, vol. 94 (3), pp. 485–514. DOI: 10.1111/1468-0009.12210
8. Drobizhev M.Yu. Time of meta-analyzes and the effectiveness of antidepressants in depression. Sotsial’naya i klinicheskaya psikhiatriya, 2017, no. 4, pp. 81–88 (in Russ.).
9. Mendelevich V.D. The benefits and harms of electronic cigarettes through the prism of various therapeutic methodologies. Vestnik sovremennoy klinicheskoy meditsiny, 2015, no. 2, pp. 61–73 (in Russ.).
10. Krylov V.I. Clinical psychopathology and evidence-based medicine (the problem of the methodology of diagnosis). Psikhiatriya i psikhofarmakoterapiya, 2011, no. 4, pp. 9–13 (in Russ.).
11. Shmukler A.B. Evidence-based research in psychiatry: an analysis of practical significance. Psikhiatriya i psikhofarmakoterapiya, 2012, no. 5, pp. 4–13 (in Russ.).
12. Sidhu N., Srinivasraghavan J. Ethics and Medical Practice: Why Psychiatry is Unique. Indian J. Psychiatry, 2016, vol. 58 (2), pp. 199–202. DOI: 10.4103/0019-5545.196838.=
13. Gupta M. Is Evidence-Based Psychiatry Ethical? Oxford Medicine Online, 2014, 214 p.
14. Neznanov N.G., Kotsyubinskiy A.P., Kotsyubinskiy D.A. The crisis of natural science and humanitarian approaches in psychiatry. Obozrenie psikhiatrii i meditsinskoy psikhologii, 2019, no. 1, pp. 8–15 (in Russ.).
15. Cipriani A., Furukawa T.A., Salanti G., Chaimani A., Atkinson L.Z., Ogawa Y., Leucht S., Ruhe H.G., Turner E.H., Higgins J.P.T., Egger M., Takeshima N., Hayasaka Y., Imai H., Shinohara K., Tajika A., Ioannidis J.P.A., Geddes J.R. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet, 2018, vol. 7 (391), pp. 1357–1366. DOI: 10.1016/S0140-6736(17)32802-7
16. Rudolfer M.V. Recent Findings of the Comparative Efficacy and Tolerability of Antidepressants for Major Depressive Disorder: Do We Now Know What to Prescribe? CNS Drugs, 2018, vol. 32 (9), pp. 807–811. DOI: 10.1007/s40263-018-0563-z
17. Gøtzsche P.C. Antidepressants are addictive and increase the risk of relapse. BMJ, 2016, vol. 352, p. 574. DOI: https://doi.org/10.1136/bmj.i574
18. Burki T. The Cochrane board votes to expel Peter Gøtzsche. Lancet, 2018, vol. 29 (392), pp. 1103–1104. DOI: 10.1016/S0140-6736(18)32351-1
19. Zorin N.A. Methodological self-deception. Does it make sense to quasi-measure human feelings and sensations? Nevrologicheskiy vestnik, 2018, no. 4, pp. 19-22 (in Russ.).
20. Chon M-W., Lee J., Chung S., Kim Y., Kim H-W. Prescription Pattern of Antidepressants for Children and Adolescents in Korea Based on Nationwide Data. J. Korean Med Sci, 2017, vol. 32 (10), pp. 1694–1701. DOI: 10.3346/jkms.2017.32.10.1694
21. Field R.I. The FDA’s New Guidance for Off-Label Promotion Is Only a Start. P&T, 2008, vol. 33 (4), pp. 220–249.